CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Phase 0 Unknown 12 enrolled Peking Union Medical College Hospital

NaSingle-groupOpen-labelTreatment

Summary

Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.

Timeline

Start: 2023-06-19
Primary completion: 2024-05-30
Completion: 2025-05-30

Publications

Li M, Zhao J, Lu ZJ, Ning C, Jiang N, Zhang Y, Li Y, Feng Y, Wang Q, Xu D, Leng X, Li J, Zhang S, Wang Z, Peng L, Tian X, Lv L, Zhou D, Zeng X. Anti-CD19 CAR T cell therapy for refractory SLE-ITP. Med. 2026 Apr 10;7(4):101039. doi: 10.1016/j.medj.2026.101039. Epub 2026 Mar 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CNCT19	Cell therapy	2.5e+07 cells	—
Subject	CNCT19	Cell therapy	5e+07 cells	—
Background	Cyclophosphamide	Other / unclassified	500 mg/m2	—
Background	Fludarabine	Small molecule	25 mg/m2	—
Background	Fludarabine	Small molecule	30 mg/m2	—

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Summary

Timeline

Publications

Drugs

Indications